Traders should monitor the ACC presentation for any data suggesting expanded clinical utility of VASCEPA, particularly in high-risk subgroups or via novel mechanisms like Lp(a) oxidation inhibition, which could influence future prescribing patterns or payer coverage, though no immediate revenue catalyst is expected.
AMRN drugs
AMRN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $15.42entry
- T+1 · 8mo ago +0.65%α +0.38% · $15.52
- T+5 · 8mo ago −5.32%α −3.28% · $14.60
- T+20 · 7mo ago −5.64%α −9.42% · $14.55
- T+60 · 5mo ago −7.91%α −18.40% · $14.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Amarin Corporation announced that additional subgroup and mechanistic data from the REDUCE-IT trial will be presented at the American College of Cardiology's 2026 Scientific Session. The data include analyses on icosapent ethyl's efficacy in high-risk cardiovascular patients and its effect on lipoprotein(a) oxidation, reinforcing the drug's biologic activity beyond triglyceride lowering.
Key Facts
- Additional REDUCE-IT subgroup and mechanistic data will be presented at ACC 2026 in New Orleans (March 28–30, 2026).
- Oral presentation on icosapent ethyl efficacy in extreme cardiovascular risk patients scheduled for March 29.
- Poster on EPA’s inhibition of oxidized lipoprotein(a) at elevated levels to be presented March 28.
- No new financial results, guidance changes, regulatory decisions, or commercial updates were disclosed.
- VASCEPA has been prescribed over 25 million times in the U.S. and is approved in multiple global markets.
Financial Impact
No immediate financial impact; data may support long-term clinical adoption and reimbursement discussions.
Risk Factors
- No new efficacy or safety data beyond previously published REDUCE-IT results; limited incremental impact.
- Forward-looking statements are speculative and subject to risks including competition, reimbursement challenges, and lack of strategic partnerships.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256251 |
Track record
8 reports on AMRN
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 28, 202619d ago 8-K Neutral 5/10 No price data
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
- Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
- Aug 28, 202611w ago Press Release Neutral 4/10 Entry $13.97 Now $11.31 −19.04% settles Nov 23
- Jun 4, 202623w ago Court Ruling Bearish 7/10 Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
- Apr 29, 202628w ago 8-K Neutral 4/10 Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
- Mar 16, 202635w ago Press Release Neutral 4/10 Viewing Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
- Feb 25, 202637w ago 8-K Bearish 6/10 Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers